Wide coverage in the media about a breakthrough by Ernest Giralt’s group that was presented yesterday in Angewandte Chemie. Specifically, this group has developed and patented a peptide shuttle able to transport substances to the brain. This shuttle has the capacity to cross the blood-brain barrier, a natural defence structure that prevents substances from passing into the brain, thus protecting it against infection. However, this barrier is also a severe obstacle for therapeutics as 98% of promising drugs for the treatment of central nervous system cannot cross it. “Many companies could recover promising molecules that were once discarded and attach them to our shuttles,” comment the researchers.